We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies Terms in Final Guidance on ANDA Submissions
FDA Clarifies Terms in Final Guidance on ANDA Submissions
The FDA unveiled a final guidance yesterday on referencing approved drug products in Abbreviated New Drug Application (ANDA) submissions that seeks to clear up confusion commenters expressed about draft guidance the agency issued Jan. 17, 2017.